New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers
NCT ID NCT05752552
First seen Apr 07, 2026 · Last updated Jun 21, 2026 · Updated 9 times
Summary
This early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. About 55 participants will take DO-2 pills, and researchers will monitor side effects and any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Antoine Lacassagne
NOT_YET_RECRUITINGNice, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Universitaire De Rennes
RECRUITINGRennes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
RECRUITINGRotterdam, Netherlands
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpitaux Universitaires de Marseille Timone
NOT_YET_RECRUITINGMarseille, 13385, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Cœur Poumon - CHU Lille
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Roi Albert II - UC Louvain
RECRUITINGBrussels, Belgium
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Radboud UMC
RECRUITINGNijmegen, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
RECRUITINGLeuven, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZA
RECRUITINGEdegem, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitair Ziekenhuis Gent
RECRUITINGGhent, 9000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DO-2 (a MET kinase inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for patients with advanced solid tumors that have specific MET mutations.
What could go wrong
This is an early Phase 1 trial with only 55 participants, so it is primarily testing safety and dosing. It may not show strong anti-tumor effects, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.